Brian Tran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Brian Tran has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Caitlin M. O'Connor
Division of Genetic Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA
44 shared publications - Goutham Narla
University of Michigan
44 shared publications - Gabrielle Hodges Onishi
Division of Genetic Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA
42 shared publications - Alexis Harold
Division of Genetic Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA
41 shared publications - Brynne Raines
Division of Genetic Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA
41 shared publications - Catherine G. Callahan
Division of Genetic Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA
41 shared publications
Latest Publications
- 14 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (871)
Restoration of PP2A AαB56αC trimer formation by RPT04402 molecular glue in high-grade uterine cancer
The incidence and mortality of high-grade endometrial cancers are increasing, and heterozygous hotspot mutations in PPP2R1A are drivers of the most aggressive forms of uterine cancer. PPP2R1A encodes the Aα scaffolding subunit of the heterotrimeric phosphatase PP2A. These recurrent mutations, specifically at the Pro 179 and Ser 256 residues, disrupt the binding of tumor-suppressive substrate-directing B56 and B55 subunits to the PP2A scaffolding subunit while maintaining binding to other regulatory subunits. Here, we identified a series of molecular glues that correct PP2A trimer formation in the context of the P179R (Pro 179 →Arg) and S256F (Ser 256 →Phe) mutants. A small-molecule library was designed to fit into the pocket at the binding interface of the Aα/B56α/C heterotrimer. The lead molecule, RPT04402, promoted B56α heterotrimerization to the Aα P179R and Aα S256F mutant scaffolds. In mice, RPT04402 treatment drove tumor regressions and extended median survival in multiple independent mutant cell lines and patient-derived xenografts, proving a robust single-agent activity. This activity was abrogated upon knockout of B56α. Combined, these data demonstrate that PP2A molecular glues are a promising first-in-class therapy that might benefit patients with PPP2R1A mutant uterine cancer by targeting a driver of this aggressive disease.
- 14 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (871)
Restoration of PP2A AαB56αC trimer formation by RPT04402 molecular glue in high-grade uterine cancer
The incidence and mortality of high-grade endometrial cancers are increasing, and heterozygous hotspot mutations in PPP2R1A are drivers of the most aggressive forms of uterine cancer. PPP2R1A encodes the Aα scaffolding subunit of the heterotrimeric phosphatase PP2A. These recurrent mutations, specifically at the Pro 179 and Ser 256 residues, disrupt the binding of tumor-suppressive substrate-directing B56 and B55 subunits to the PP2A scaffolding subunit while maintaining binding to other regulatory subunits. Here, we identified a series of molecular glues that correct PP2A trimer formation in the context of the P179R (Pro 179 →Arg) and S256F (Ser 256 →Phe) mutants. A small-molecule library was designed to fit into the pocket at the binding interface of the Aα/B56α/C heterotrimer. The lead molecule, RPT04402, promoted B56α heterotrimerization to the Aα P179R and Aα S256F mutant scaffolds. In mice, RPT04402 treatment drove tumor regressions and extended median survival in multiple independent mutant cell lines and patient-derived xenografts, proving a robust single-agent activity. This activity was abrogated upon knockout of B56α. Combined, these data demonstrate that PP2A molecular glues are a promising first-in-class therapy that might benefit patients with PPP2R1A mutant uterine cancer by targeting a driver of this aggressive disease.
- Open Access
- 15 September 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (20)
Stabilization of the PP2A-B56α complex overcomes venetoclax-azacitidine resistance by impairing OXPHOS in AML
Cell metabolic rewiring is associated with resistance to venetoclax-azacitidine (Ven-Aza) combination therapy and relapse in patients with acute myeloid leukemia (AML). Drug-resistant cells exhibit an enhanced reliance on oxidative phosphorylation (OXPHOS) for energy production. Therefore, impairing mitochondrial metabolism represents an exciting strategy to face this unmet clinical need. We recently demonstrated that the specific activation of the phosphatase PP2A-B56α enhances the proapoptotic efficacy of venetoclax in AML. Here, through leveraging unbiased multi-omics–based approaches and using both genetic and pharmacological tools, we define key roles for the tumor suppressor PP2A-B56α complex in OXPHOS regulation and treatment response in disease-relevant AML models. From a translational perspective, the specific stabilization of PP2A-B56α heterocomplex with the potentially novel PP2A molecular glue activator, RPT04402, reduces OXPHOS levels in treatment-resistant AML cells and improves treatment response in both Ven-Aza–sensitive and –resistant AML cell lines, primary cells, and in vivo models. Together, our work supports further research on targeted combination therapy approaches based on PP2A-B56α stabilization to counteract OXPHOS-related treatment resistance and improve AML responses in a patient population with historically poor outcomes.
- 15 September 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (20)
Open AccessStabilization of the PP2A-B56α complex overcomes venetoclax-azacitidine resistance by impairing OXPHOS in AML
Cell metabolic rewiring is associated with resistance to venetoclax-azacitidine (Ven-Aza) combination therapy and relapse in patients with acute myeloid leukemia (AML). Drug-resistant cells exhibit an enhanced reliance on oxidative phosphorylation (OXPHOS) for energy production. Therefore, impairing mitochondrial metabolism represents an exciting strategy to face this unmet clinical need. We recently demonstrated that the specific activation of the phosphatase PP2A-B56α enhances the proapoptotic efficacy of venetoclax in AML. Here, through leveraging unbiased multi-omics–based approaches and using both genetic and pharmacological tools, we define key roles for the tumor suppressor PP2A-B56α complex in OXPHOS regulation and treatment response in disease-relevant AML models. From a translational perspective, the specific stabilization of PP2A-B56α heterocomplex with the potentially novel PP2A molecular glue activator, RPT04402, reduces OXPHOS levels in treatment-resistant AML cells and improves treatment response in both Ven-Aza–sensitive and –resistant AML cell lines, primary cells, and in vivo models. Together, our work supports further research on targeted combination therapy approaches based on PP2A-B56α stabilization to counteract OXPHOS-related treatment resistance and improve AML responses in a patient population with historically poor outcomes.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Key Resources Table from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
Table of key resources and reagents used in this manuscript.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessKey Resources Table from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
Table of key resources and reagents used in this manuscript.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supp Figure 11 from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
Supp Figure 11 from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupp Figure 11 from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
Supp Figure 11 from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supp Figure 9 from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
Supp Figure 9 from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupp Figure 9 from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
Supp Figure 9 from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supp Figure 5 from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
Supp Figure 5 from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupp Figure 5 from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
Supp Figure 5 from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
B56-alpha OE Vector Map from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
Vector map for the B56-alpha overexpression (OE) plasmid
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessB56-alpha OE Vector Map from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
Vector map for the B56-alpha overexpression (OE) plasmid
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supp Figure 12 from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
Supp Figure 12 from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupp Figure 12 from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer
Supp Figure 12 from Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer